Rapport Therapeutics director James Healy buys $20.4 million of shares
Open market purchase reported on Form 4, filed Oct 30, 2026.
Snapshot
James Healy, a director of Rapport Therapeutics (RAPP), bought 969,480 shares in open market purchases on Oct 28, 2026, about $20.4 million at an average price of $21.00 a share, according to a Form 4 filed with the SEC on Oct 30, 2026.
- Independent Research
Market Data
| Company | 1D % | Price |
|---|---|---|
| ($RAPP) | ▲ +3.47% | 25.05 |
as of 16:00 ET · Realtime derived data
What We Know
The filing lists 4 open market purchase lines: • Oct 28, 2026: 952,380 shares at $21.00. • Oct 28, 2026: 6,395 shares at $21.00. • Oct 28, 2026: 3,772 shares at $21.00. • Oct 28, 2026: 6,933 shares at $21.00.
After the last purchase, the filing reports 25,267 shares held indirectly in that account.
Octans View
An open market purchase is made with the insider's own money at the market price, unlike option exercises or stock awards, which this brief excludes. The filing does not say why the insider bought.
Bear Case · Room for Disagreement
Limits. Insiders must report trades within two business days; this brief covers one filing and does not net it against sales by the same person or other insiders. Prices are as filed; where a line shows a weighted average, the filing's footnotes give the range.
Method and source. Octans Research reads the structured Form 4 filed with the SEC, keeps open market purchases (code P) only, and computes the total value and the average price from the filed share counts and prices. The filed price must sit within 25% of the closing price on the trade date. The text is generated by a fixed template; no model wrote it.
Chart
Sources
- [1]SEC EDGAR — Form 4 filed by James Healy for Rapport Therapeutics, Oct 30, 2026
These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.
$20.4M
More on $RAPP
4 reports
Rapport Therapeutics director Steven M Paul buys $974,000 of shares
Open market purchase reported on Form 4, filed Oct 22, 2026.
Lycia Therapeutics 10% owner Venrock Healthcare Capital Partners III L.P. buys $645,000 of shares
Open market purchase reported on Form 4, filed Oct 30, 2026.
Corebridge Financial 10% owner Nippon Life Insurance Co buys $8.7 million of shares
Open market purchase reported on Form 4, filed Oct 30, 2026.
SEC filing red flags, week of Oct 26 to 30, 2026
1 late filing notice, 1 non reliance warning, 3 auditor changes, 10 listing deficiency notices and 8 going concern warnings at companies listed on Nasdaq or the NYSE, each line matched to the filing.